APA (7th ed.) Citation

Salwender, H., Bertsch, U., Weisel, K., Duerig, J., Kunz, C., Benner, A., . . . Goldschmidt, H. (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: A randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC.

Chicago Style (17th ed.) Citation

Salwender, Hans, et al. Rationale and Design of the German-speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/consolidation and Lenalidomide Maintenance in Patients with Newly Diagnosed Myeloma. BMC, 2019.

MLA (8th ed.) Citation

Salwender, Hans, et al. Rationale and Design of the German-speaking Myeloma Multicenter Group (GMMG) Trial HD6: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/consolidation and Lenalidomide Maintenance in Patients with Newly Diagnosed Myeloma. BMC, 2019.